Similar to ovarian and breast cancers, some sporadic prostate, pancreatic and other tumors also possess DNA damage response defects due to mutation or epigenetic inactivation of HR components, suggesting that PARP inhibitors might be more broadly applicable. The gene discussed is PARP1; the disease is breast cancer.